Phaxiam

Press release

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).

Press release

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET

News

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Press release

PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares

TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share

Press release

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains

Press release

PHAXIAM Receives Compliance Notice from Nasdaq

Press release

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration

Press release

PHAXIAM Provides Business and Financial Update – For the First Half of 2023

Press release

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

Press release

PHAXIAM Therapeutics announces the completion of its reverse share split

Press release

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

Press release

PHAXIAM Therapeutics announces a reverse share split of its shares

News & events